ScreenerHero

SIBNSI-BONE, Inc.

NAS · US · Healthcare · Medical Devices · si-bone.com
20.00USD+0.20%Mkt Cap: 885.21M $P/E: —

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It of…

Industry Peers

Medical Devices
Screen all
ABT
Abbott Laboratories
$203.22BUSDP/E 37.8
SYK
Stryker Corporation
$125.74BUSDP/E 34.0
MDT
Medtronic plc
$118.91BUSDP/E 24.9
BSX
Boston Scientific Corporation
$71.03BUSDP/E 19.8
SHL
Siemens Healthineers AG
$48.43BUSDP/E 19.9
EW
Edwards Lifesciences Corporation
$52.11BUSDP/E 53.9
DXCM
DexCom, Inc.
$34.85BUSDP/E 36.5
GEHC
GE HealthCare Technologies Inc. Common Stock
$34.04BUSDP/E 17.2
PHIA
Koninklijke Philips N.V.
$25.08BUSDP/E 20.7
PHG
Koninklijke Philips N.V.
$26.90BUSDP/E 20.7
STE
STERIS plc
$23.19BUSDP/E 29.1
ZBH
Zimmer Biomet Holdings, Inc.
$19.26BUSDP/E 24.5
PEN
Penumbra, Inc.
$12.75BUSDP/E 79.7
SNN
Smith & Nephew plc
$12.40BUSDP/E 20.1
GMED
Globus Medical, Inc.
$11.29BUSDP/E 21.5
GKOS
Glaukos Corporation
$10.95BUSD
SN
Smith & Nephew plc
$9.84BUSDP/E 20.0
PODD
Insulet Corporation
$10.28BUSDP/E 27.5
BIO
Bio-Rad Laboratories, Inc.
$10.22BUSDP/E 46.5
DEMANT
Demant A/S
$8.82BUSDP/E 25.0
HeadlineSourceTime
Older
SI-BONE (SIBN) Q2 2026 Earnings Call Transcript

Record physician engagement and broad-based demand drive 15% revenue growth.

Motley Fool
Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?

The consensus price target hints at a 38.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks
SI-BONE, Inc. Q2 2026 Earnings Call Summary

Moby summary of SI-BONE, Inc.'s Q2 2026 earnings call

Moby
SI-BONE Inc (SIBN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Raised ...

SI-BONE Inc (SIBN) delivers 15% revenue growth, narrows net loss, and raises full-year guidance on robust procedure volume and promising reimbursement tailwinds.

GuruFocus.com
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates

Si-Bone (SIBN) delivered earnings and revenue surprises of +40.00% and +1.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
SiBone Q2 Earnings Call Highlights

SiBone (NASDAQ:SIBN) reported second-quarter 2026 revenue growth of 15.2% and narrowed its net loss as procedure volumes increased across its U.S. business and international demand rose for its expanded product portfolio. Worldwide revenue reached $56 million for the quarter ended June 30, while U.

MarketBeat
Bears are Losing Control Over Si-Bone (SIBN), Here's Why It's a 'Buy' Now
Zacks
Wall Street Analysts Predict a 71.13% Upside in Si-Bone (SIBN): Here's What You Should Know
Zacks
How Much Upside is Left in Si-Bone (SIBN)? Wall Street Analysts Think 65.27%

The consensus price target hints at a 65.3% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks
Why Si-Bone Stock Soared by Almost 20% on Tuesday

It's off to a roaring start as far as the financial year is concerned.

Motley Fool